Background
The impact of long-acting nitrates on the extent and severity of stress-induced myocardial ischemia is not well described,
especially after long-term treatment.
Methods
Forty patients with chronic stable angina and reversible ischemia on an exercise stress myocardial perfusion single photon
emission computed tomography (ex-SPECT) were prospectively studied in a 6-week period. At baseline, rest thallium-201/exercise
stress technetium 99m sestamibi SPECT was performed, followed by treatment with extended-release isosorbide 5-mononitrate
(5-ISMN, Imdur). Follow-up ex-SPECT was performed 5 days and 6 weeks after the initiation of therapy with extended-release
5-ISMN. The exercise treadmill testing (ETT) protocol and exercise duration of the follow-up studies were the same as that
of the baseline ETT. Defect extent and severity were analyzed both by means of an automated quantitative method, with CEqual
software, and visually, with a 20-segment scoring system (which was also used to derive a summed stress score [SSS]).
Results
In the 6-week study period, significant reductions occurred in both the extent and the severity of exercise-induced ischemia
by means of quantitative SPECT (13.8% [P<.0003] and 12.7% [P<.0003], respectively). There was no significant change in these variables between stages 2 (day 5) and 3 (6 weeks), indicating
no development of tolerance to the nitrate effect. Similar reductions were noted by means of the visual analysis (SSS reduction
of 13.0% [P<.002]) in the entire study period.
Conclusions
Patients with chronic-stable-angina treated with a long-acting nitrate demonstrate improvement in myocardial perfusion defect
extent and severity in an extended period by means of both visual and quantitative analysis of sequential exercise testing
to the same ratepressure product end point.
Key Words Isosorbide-5-mononitrate - technetium-99m sestamibi - myocardial perfusion SPECT - coronary artery disease - quantitative analysis - exercise-induced ischemia
Presented in part at the 69th Annual Scientific Sessions of the American Heart Association, New Orleans, La, November 1996.
Cedars-Sinai Medical Center receives royalties, a portion of which are distributed to Mr Van Train and Dr Berman, for the
CEqual software described in this manuscript.